What is Wedbush’s Estimate for APRE FY2029 Earnings?

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Equities research analysts at Wedbush issued their FY2029 earnings per share estimates for shares of Aprea Therapeutics in a research note issued on Tuesday, March 25th. Wedbush analyst R. Driscoll anticipates that the company will post earnings of $2.19 per share for the year. Wedbush has a “Outperform” rating and a $11.00 price target on the stock. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($2.55) per share.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings results on Tuesday, March 25th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.20. The company had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.15 million. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Aprea Therapeutics in a research report on Wednesday, January 15th.

Aprea Therapeutics Stock Down 1.8 %

APRE stock opened at $2.20 on Thursday. The company’s fifty day simple moving average is $3.06 and its 200 day simple moving average is $3.24. Aprea Therapeutics has a 12-month low of $2.15 and a 12-month high of $6.80. The firm has a market cap of $11.96 million, a price-to-earnings ratio of -0.78 and a beta of 0.82.

Hedge Funds Weigh In On Aprea Therapeutics

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets bought a new stake in Aprea Therapeutics in the 4th quarter valued at about $43,000. LPL Financial LLC acquired a new position in shares of Aprea Therapeutics during the fourth quarter valued at about $53,000. Landscape Capital Management L.L.C. bought a new stake in shares of Aprea Therapeutics during the fourth quarter worth about $116,000. Finally, Stonepine Capital Management LLC raised its holdings in shares of Aprea Therapeutics by 8.8% in the 4th quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock worth $491,000 after acquiring an additional 12,047 shares during the last quarter. Institutional investors and hedge funds own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.